Zoetis Inc (NYSE:ZTS) has been assigned a consensus rating of “Buy” from the sixteen research firms that are presently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $123.29.

ZTS has been the topic of several recent analyst reports. Argus set a $140.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Wednesday, September 4th. SunTrust Banks upped their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a report on Tuesday, August 13th. Craig Hallum upped their price target on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Guggenheim initiated coverage on shares of Zoetis in a report on Thursday, May 23rd. They issued a “buy” rating and a $114.00 price target on the stock. Finally, Barclays upped their price target on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th.

Shares of ZTS stock traded down $0.07 on Friday, hitting $121.62. The stock had a trading volume of 47,922 shares, compared to its average volume of 1,747,444. The firm has a market capitalization of $58.75 billion, a price-to-earnings ratio of 38.86, a P/E/G ratio of 3.11 and a beta of 0.87. The stock’s 50 day moving average is $122.69 and its 200-day moving average is $108.79. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. Zoetis has a 52-week low of $78.90 and a 52-week high of $130.08.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. Equities analysts expect that Zoetis will post 3.57 earnings per share for the current year.

In other Zoetis news, insider Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $113.09, for a total transaction of $692,450.07. Following the sale, the insider now directly owns 46,812 shares of the company’s stock, valued at $5,293,969.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the sale, the executive vice president now directly owns 33,190 shares in the company, valued at $4,181,608.10. The disclosure for this sale can be found here. Insiders sold 28,209 shares of company stock worth $3,428,025 over the last ninety days. 0.29% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of ZTS. Glassman Wealth Services increased its holdings in shares of Zoetis by 306.5% in the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after acquiring an additional 190 shares during the period. JJJ Advisors Inc. bought a new position in Zoetis in the 2nd quarter valued at about $25,000. Prestige Wealth Management Group LLC bought a new position in Zoetis in the 2nd quarter valued at about $27,000. Altshuler Shaham Ltd grew its position in Zoetis by 198.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after buying an additional 169 shares in the last quarter. Finally, Next Capital Management LLC grew its position in Zoetis by 156.5% in the 2nd quarter. Next Capital Management LLC now owns 295 shares of the company’s stock valued at $33,000 after buying an additional 180 shares in the last quarter. 90.25% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: What is a Market Correction?

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.